{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:56:01Z","timestamp":1790657761944,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12325-026-03657-6","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:34:20Z","timestamp":1783931660000},"page":"4559-4574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patterns and Determinants of Time to First DMARD Prescription in US Adults with Rheumatoid Arthritis: A Retrospective Cohort Study Using a Large Electronic Health Record Database"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8430-4279","authenticated-orcid":false,"given":"Zuhair A.","family":"Alqahtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan O.","family":"Almadfaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter","family":"Garami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomo","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia R.","family":"Wigle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L.","family":"Hincapie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff J.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"10055","key":"3657_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338.","journal-title":"Lancet"},{"key":"3657_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03251-z","author":"T Fujii","year":"2024","unstructured":"Fujii T, Murata K, Onizawa H, et al. Management and treatment outcomes of rheumatoid arthritis in the era of biologic and targeted synthetic therapies: evaluation of 10-year data from the KURAMA Cohort. Arthritis Res Ther. 2024. https:\/\/doi.org\/10.1186\/s13075-023-03251-z.","journal-title":"Arthritis Res Ther"},{"issue":"13","key":"3657_CR3","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis. JAMA. 2018;320(13):1360.","journal-title":"JAMA"},{"issue":"1","key":"3657_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1\u201326.","journal-title":"Arthritis Rheumatol"},{"key":"3657_CR5","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"3657_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/jpbi2020007","volume":"2","author":"ZA Alqahtani","year":"2025","unstructured":"Alqahtani ZA, Yue X, Guo JJ. Utilization, expenditure, and price trends of nonbiologic and biologic disease-modifying antirheumatic drugs in the US Medicaid Programs: an empirical data analysis of over three decades. J Pharm BioTech Ind. 2025;2(2):7.","journal-title":"J Pharm BioTech Ind"},{"issue":"5","key":"3657_CR7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.semarthrit.2018.07.003","volume":"48","author":"L Kimsey","year":"2019","unstructured":"Kimsey L, et al. Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: an analysis of United States Military Health System TRICARE beneficiaries. Semin Arthritis Rheum. 2019;48(5):821\u20137.","journal-title":"Semin Arthritis Rheum"},{"issue":"9313","key":"3657_CR8","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","volume":"359","author":"HK Choi","year":"2002","unstructured":"Choi HK, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359(9313):1173\u20137.","journal-title":"Lancet"},{"issue":"5","key":"3657_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/annrheumdis-2014-206047","volume":"74","author":"JAB van Nies","year":"2015","unstructured":"van Nies JAB, et al. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts. Ann Rheum Dis. 2015;74(5):806\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"3657_CR10","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1002\/art.27692","volume":"62","author":"MP van der Linden","year":"2010","unstructured":"van der Linden MP, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010;62(12):3537\u201346.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"3657_CR11","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924\u201339.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"3657_CR12","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3657_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2020.07.009","volume":"88","author":"J Kedra","year":"2021","unstructured":"Kedra J, et al. Time to initiation of biologic disease-modifying antirheumatic drugs in the French cohort ESPOIR. Jt Bone Spine. 2021;88(1):105060.","journal-title":"Jt Bone Spine"},{"issue":"8 Spec No.","key":"3657_CR14","first-page":"Sp279","volume":"24","author":"M Bonafede","year":"2018","unstructured":"Bonafede M, et al. Disease-modifying antirheumatic drug initiation among patients newly diagnosed with rheumatoid arthritis. Am J Manag Care. 2018;24(8 Spec No.):Sp279\u201385.","journal-title":"Am J Manag Care"},{"key":"3657_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40744-020-00203-w","volume":"7","author":"E Sullivan","year":"2020","unstructured":"Sullivan E, et al. Biologic disease-modifying antirheumatic drug prescription patterns for rheumatoid arthritis among United States physicians. Rheumatol Ther. 2020;7:383\u2013400.","journal-title":"Rheumatol Ther"},{"issue":"11","key":"3657_CR16","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1007\/s00296-018-4161-7","volume":"38","author":"A Steffen","year":"2018","unstructured":"Steffen A, et al. Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data. Rheumatol Int. 2018;38(11):2111\u201320.","journal-title":"Rheumatol Int"},{"issue":"1","key":"3657_CR17","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik P, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198\u2013206.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3657_CR18","volume":"14","author":"NJ Peterman","year":"2022","unstructured":"Peterman NJ, et al. Evaluation of access disparities to biologic disease-modifying antirheumatic drugs in rural and urban communities. Cureus. 2022;14(6):e26448.","journal-title":"Cureus"},{"key":"3657_CR19","doi-asserted-by":"crossref","unstructured":"Ludwig RJ, Anson M, Zirpel H, et al. A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX. Front Pharmacol. 2025;16:1516126.","DOI":"10.3389\/fphar.2025.1516126"},{"key":"3657_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1146\/annurev-publhealth-032315-021353","volume":"37","author":"JA Casey","year":"2016","unstructured":"Casey JA, et al. Using electronic health records for population health research: a review of methods and applications. Annu Rev Public Health. 2016;37:61\u201381.","journal-title":"Annu Rev Public Health"},{"issue":"8 Suppl 3","key":"3657_CR21","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1097\/MLR.0b013e31829b1dbd","volume":"51","author":"WR Hersh","year":"2013","unstructured":"Hersh WR, et al. Caveats for the use of operational electronic health record data in comparative effectiveness research. Med Care. 2013;51(8 Suppl 3):S30\u20137.","journal-title":"Med Care"},{"issue":"4","key":"3657_CR22","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s10067-025-07360-9","volume":"44","author":"B Mikaeili","year":"2025","unstructured":"Mikaeili B, et al. Safety of Janus kinase inhibitors in rheumatoid arthritis: a disproportionality analysis using FAERS database from 2012 to 2022. Clin Rheumatol. 2025;44(4):1467\u201374.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"3657_CR23","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/acr2.11625","volume":"5","author":"J Lee","year":"2023","unstructured":"Lee J, et al. Initiation of disease-modifying antirheumatic drugs in older Medicare beneficiaries with new diagnosis of late-onset rheumatoid arthritis. ACR Open Rheumatol. 2023;5(12):694\u2013700.","journal-title":"ACR Open Rheumatol"},{"issue":"2","key":"3657_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40744-015-0019-6","volume":"2","author":"DA Pappas","year":"2015","unstructured":"Pappas DA, et al. Delays in initiation of disease-modifying therapy in rheumatoid arthritis patients: data from a US-based registry. Rheumatol Ther. 2015;2(2):153\u201364.","journal-title":"Rheumatol Ther"},{"issue":"4","key":"3657_CR25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1136\/ard.2011.155416","volume":"71","author":"RJ Stack","year":"2012","unstructured":"Stack RJ, et al. Delays in help seeking at the onset of the symptoms of rheumatoid arthritis: a systematic synthesis of qualitative literature. Ann Rheum Dis. 2012;71(4):493\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3657_CR26","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1186\/ar2591","volume":"11","author":"T Sokka","year":"2009","unstructured":"Sokka T, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther. 2009;11(1):R7.","journal-title":"Arthritis Res Ther"},{"key":"3657_CR27","doi-asserted-by":"publisher","first-page":"414","DOI":"10.37765\/ajmc.2025.89774","volume":"31","author":"GC Wright","year":"2025","unstructured":"Wright G, et al. US health care disparities in immunology biologics access: a systematic review. Am J Manag Care. 2025;31:414\u201320.","journal-title":"Am J Manag Care"},{"issue":"2","key":"3657_CR28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/acr.20674","volume":"64","author":"DH Solomon","year":"2012","unstructured":"Solomon DH, et al. Use of disease-modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey. Arthritis Care Res (Hoboken). 2012;64(2):184\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"3657_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.14745","volume":"2","author":"A Strait","year":"2019","unstructured":"Strait A, et al. Demographic characteristics of participants in rheumatoid arthritis randomized clinical trials: a systematic review. JAMA Netw Open. 2019;2(11):e1914745.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"3657_CR30","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1001\/jama.2011.67","volume":"305","author":"G Schmajuk","year":"2011","unstructured":"Schmajuk G, et al. Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA. 2011;305(5):480\u20136.","journal-title":"JAMA"},{"issue":"12","key":"3657_CR31","first-page":"1472","volume":"22","author":"J Shafrin","year":"2016","unstructured":"Shafrin J, et al. Geographic variation in the quality and cost of care for patients with rheumatoid arthritis. J Manag Care Spec Pharm. 2016;22(12):1472\u201381.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"3657_CR32","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/art.39079","volume":"67","author":"J Yazdany","year":"2015","unstructured":"Yazdany J, et al. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D. Arthritis Rheumatol. 2015;67(6):1474\u201380.","journal-title":"Arthritis Rheumatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03657-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03657-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03657-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:14:53Z","timestamp":1790655293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03657-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3657"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03657-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zuhair A. Alqahtani, Rawan O. Almadfaa, Eszter Garami, Xiaomo Xiong, Patricia R. Wigle, Bin Huang, and Ana L. Hincapie have nothing to disclose. Jeff J. Guo is an Editorial Board member of\n                      Advances in Therapy\n                      . Jeff J. Guo was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The proposal for this study was approved by the University of Cincinnati Institutional Review Board (IRB ID 2024-0197). The University of Cincinnati and TriNetX have maintained an established agreement since 2016, allowing UC researchers to access aggregated patient records for research purposes. All data used in this study were covered under IRB approval and consisted of de-identified patient information.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}